Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

The FDA approved Zepbound (tirzepatide) as the first prescription medication specifically for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. People taking Zepbound lost ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in Otolaryngology–Head and Neck Surgery reveals that for people with sleep apnea, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Statistics show that obstructive sleep apnea (OSA ... machines are the most common treatment for OSA. This includes a sleep apnea mask which delivers a consistent stream of pressurized air ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive ... and sleep apnea may redefine treatment ...

Sleep apnea involves repeated breathing ... consider speaking with a doctor for proper diagnosis and treatment. Healthline has strict sourcing guidelines and relies on peer-reviewed studies ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep apnea medication. Zepbound or Tirzepatide is an injectable drug that the ...

Continuous positive airway pressure (CPAP) therapy, which is the most common treatment for obstructive sleep apnea (OSA), may ...

The pathophysiology of residual sleepiness in treated obstructive sleep apnoea (OSA) remains poorly understood. Animal models ...